Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.
2.

Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.

Balint BL, Nagy L.

Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):33-43. Review.

PMID:
16611163
3.

Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.

Agrawal R, Jain P, Dikshit SN.

Mini Rev Med Chem. 2012 Feb;12(2):87-97. Review.

PMID:
22372600
4.

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.

Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley RT, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP.

Mol Pharmacol. 2008 Jan;73(1):62-74. Epub 2007 Oct 16.

5.

Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.

Cho MC, Lee K, Paik SG, Yoon DY.

PPAR Res. 2008;2008:679137. doi: 10.1155/2008/679137.

6.

Peroxisome proliferator-activated receptors as attractive antiobesity targets.

Zhang F, Lavan B, Gregoire FM.

Drug News Perspect. 2004 Dec;17(10):661-9. Review.

PMID:
15696231
7.
8.

T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.

Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.

J Biol Chem. 2008 Apr 4;283(14):9168-76. doi: 10.1074/jbc.M800104200. Epub 2008 Feb 7.

9.

Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome.

Ramachandran U, Kumar R, Mittal A.

Mini Rev Med Chem. 2006 May;6(5):563-73. Review.

PMID:
16719831
10.

INT131: a selective modulator of PPAR gamma.

Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, Lindstrom M, Liu J, Biermann DH, Jaen J, Walker NP, Learned RM, Chen JL, Li Y.

J Mol Biol. 2009 Mar 13;386(5):1301-11.

PMID:
19452630
11.

Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.

Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA.

Diabetes. 2006 Sep;55(9):2523-33.

12.

Evolution of peroxisome proliferator-activated receptor agonists.

Chang F, Jaber LA, Berlie HD, O'Connell MB.

Ann Pharmacother. 2007 Jun;41(6):973-83. Epub 2007 May 22. Review.

PMID:
17519293
14.

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.

Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabilès N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P.

Circulation. 2004 Nov 16;110(20):3259-69. Epub 2004 Nov 8.

15.

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ.

Cardiovasc Diabetol. 2005 Sep 16;4:14. Review.

16.

Peroxisome proliferator-activated receptors, orphans with ligands and functions.

Schoonjans K, Martin G, Staels B, Auwerx J.

Curr Opin Lipidol. 1997 Jun;8(3):159-66. Review.

PMID:
9211064
18.

Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.

Vázquez M, Silvestre JS, Prous JR.

Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):515-23. Review.

PMID:
12500431
19.

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA.

J Biol Chem. 1995 Jun 2;270(22):12953-6.

20.

Interdomain communication regulating ligand binding by PPAR-gamma.

Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA.

Nature. 1998 Nov 26;396(6709):377-80.

PMID:
9845075
Items per page

Supplemental Content

Write to the Help Desk